IGF Bioregulation System in Benign and Malignant Thyroid Nodular Disease: A Systematic Review

Overview

Journal In Vivo

Specialty Oncology

Date 2020 Nov 4

PMID 33144411

Citations 4

Authors

Apostolos Karagiannis

Eva Kassi

Antonios Chatzigeorgiou

Michael Koutsilieris

Affiliations

Soon will be listed here.

Abstract

Background/aim: The insulin-like growth factor bioregulation system is implicated in cancer biology. Herein, we aim to review the evidence on the expression of the insulin-like growth factor 1 and 2 (IGF1 and IGF2), their receptors (IGF-Rs) and IGF-binding proteins (IGFBPs) in thyroid tissue and their possible association with benign and malignant thyroid nodular diseases.

Materials And Methods: We systematically reviewed Pubmed and Scopus databases up to May 2020. A total of 375 articles were retrieved and analyzed.

Results: Among 375 articles, 45 were included in this systematic review study. IGF1 was investigated in 31 studies, IGF2 in 1, IGF1 receptor in 15 and IGF-binding proteins in 13 articles. IGF1 expression in humans was dependent on the number and compound of benign nodules as well as the method of measurement. In differentiated thyroid carcinoma, a positive correlation between IGF1 and immunohistological stage was documented in some studies while in others only a positive trend was observed. IGF-1R and IGFBPs expression was higher in malignant rather than benign lesions. There was only a positive trend for increased IGF2 expression in malignancy, while IGFBPs were in most studies statistically increased in various cancer types compared to benign nodular disease.

Conclusion: The present data demonstrate that in most studies there is statistically positive expression of IGF-1 and less of IGF-2 in thyroid cancer compared to normal thyroid tissue.

Citing Articles

A review of complex hormone regulation in thyroid cancer: novel insights beyond the hypothalamus-pituitary-thyroid axis.

Chen L, Xie T, Lei Q, Gu Y, Sun C Front Endocrinol (Lausanne). 2024; 15:1419913.

PMID: 39104813 PMC: 11298353. DOI: 10.3389/fendo.2024.1419913.

Height, Autoimmune Thyroid Disease, and Thyroid Cancer: A Mendelian Randomization Study.

Papadopoulou A, Asvold B, Burgess S, Kus A, Medici M, Sterenborg R Thyroid. 2023; 33(12):1476-1482.

PMID: 37772697 PMC: 7615364. DOI: 10.1089/thy.2023.0272.

Diosgenin From Dioscorea Nipponica Rhizoma Against Graves' Disease-On Network Pharmacology and Experimental Evaluation.

Xin J, Cheng W, Yu Y, Chen J, Zhang X, Shao S Front Pharmacol. 2022; 12:806829.

PMID: 35140607 PMC: 8819592. DOI: 10.3389/fphar.2021.806829.

Thyroid Cancer Risk Factors in Children with Thyroid Nodules: A One-Center Study.

Ben-Skowronek I, Sieniawska J, Pach E, Wrobel W, Skowronek A, Tomczyk Z J Clin Med. 2021; 10(19).

PMID: 34640473 PMC: 8509812. DOI: 10.3390/jcm10194455.

References

Jin L, Seys A, Zhang S, Erickson-Johnson M, Roth C, Evers B . Diagnostic utility of IMP3 expression in thyroid neoplasms: a quantitative RT-PCR study. Diagn Mol Pathol. 2010; 19(2):63-9. DOI: 10.1097/PDM.0b013e3181b6a528. View

Rekvava M, Dundua T, Kobulia M, Javashvili L, Giorgadze E . INSULIN LIKE GROWTH FACTOR 1 POSSIBLE DEPENDENCE IN PATIENTS WITH METABOLIC SYNDROME OF NODULAR PATHOLOGY OF THE THYROID GLAND. Georgian Med News. 2017; (270):46-50. View

Maiorano E, Ciampolillo A, Viale G, Maisonneuve P, Ambrosi A, Triggiani V . Insulin-like growth factor 1 expression in thyroid tumors. Appl Immunohistochem Mol Morphol. 2000; 8(2):110-9. DOI: 10.1097/00129039-200006000-00005. View

Samani A, Yakar S, LeRoith D, Brodt P . The role of the IGF system in cancer growth and metastasis: overview and recent insights. Endocr Rev. 2006; 28(1):20-47. DOI: 10.1210/er.2006-0001. View

Schmidt J, Allen N, Almquist M, Franceschi S, Rinaldi S, Tipper S . Insulin-like growth factor-i and risk of differentiated thyroid carcinoma in the European prospective investigation into cancer and nutrition. Cancer Epidemiol Biomarkers Prev. 2014; 23(6):976-85. PMC: 4046912. DOI: 10.1158/1055-9965.EPI-13-1210-T. View

Belfiore A, Pandini G, Vella V, Squatrito S, Vigneri R . Insulin/IGF-I hybrid receptors play a major role in IGF-I signaling in thyroid cancer. Biochimie. 1999; 81(4):403-7. DOI: 10.1016/s0300-9084(99)80088-1. View

Akker M, Guldiken S, Sipahi T, Palabiyik O, Tosunoglu A, Celik O . Investigation of insulin resistance gene polymorphisms in patients with differentiated thyroid cancer. Mol Biol Rep. 2014; 41(5):3541-7. DOI: 10.1007/s11033-014-3218-2. View

Sozopoulos E, Litsiou H, Voutsinas G, Mitsiades N, Anagnostakis N, Tseva T . Mutational and immunohistochemical study of the PI3K/Akt pathway in papillary thyroid carcinoma in Greece. Endocr Pathol. 2010; 21(2):90-100. DOI: 10.1007/s12022-010-9112-0. View

Slosar M, Vohra P, Prasad M, Fischer A, Quinlan R, Khan A . Insulin-like growth factor mRNA binding protein 3 (IMP3) is differentially expressed in benign and malignant follicular patterned thyroid tumors. Endocr Pathol. 2009; 20(3):149-57. DOI: 10.1007/s12022-009-9079-x. View

10.

Karagiannis A, Philippou A, Tseleni-Balafouta S, Zevolis E, Nakouti T, Tsopanomichalou-Gklotsou M . IGF-IEc Expression Is Associated With Advanced Differentiated Thyroid Cancer. Anticancer Res. 2019; 39(6):2811-2819. DOI: 10.21873/anticanres.13409. View

11.

Fuhrer D, Eszlinger M, Karger S, Krause K, Engelhardt C, Hasenclever D . Evaluation of insulin-like growth factor II, cyclooxygenase-2, ets-1 and thyroid-specific thyroglobulin mRNA expression in benign and malignant thyroid tumours. Eur J Endocrinol. 2005; 152(5):785-90. DOI: 10.1530/eje.1.01912. View

12.

Hakam A, Yeatman T, Lu L, Mora L, Marcet G, Nicosia S . Expression of insulin-like growth factor-1 receptor in human colorectal cancer. Hum Pathol. 1999; 30(10):1128-33. DOI: 10.1016/s0046-8177(99)90027-8. View

13.

Perlino E, Ciampolillo A, Maenza S, Marra E, Derobertis O, Ambrosi A . Increased expression of insulin-like growth factor 1 (IGF-1) in multinodular non toxic goiter. Oncol Rep. 2011; 3(4):753-7. DOI: 10.3892/or.3.4.753. View

14.

Philippou A, Christopoulos P, Koutsilieris D . Clinical studies in humans targeting the various components of the IGF system show lack of efficacy in the treatment of cancer. Mutat Res Rev Mutat Res. 2017; 772:105-122. DOI: 10.1016/j.mrrev.2016.09.005. View

15.

Vesely D, Astl J, Lastuvka P, Matucha P, Sterzl I, Betka J . Serum levels of IGF-I, HGF, TGFbeta1, bFGF and VEGF in thyroid gland tumors. Physiol Res. 2004; 53(1):83-9. View

16.

Liu Y, Qiang W, Liu X, Xu L, Guo H, Wu L . Association of insulin-like growth factor-1 with thyroid nodules. Oncol Lett. 2012; 2(6):1297-1301. PMC: 3406504. DOI: 10.3892/ol.2011.411. View

17.

Yan Y, Hu F, Wu W, Ma R, Huang H . Expression characteristics of proteins of IGF-1R, p-Akt, and survivin in papillary thyroid carcinoma patients with type 2 diabetes mellitus. Medicine (Baltimore). 2017; 96(12):e6393. PMC: 5371468. DOI: 10.1097/MD.0000000000006393. View

18.

Kulacoglu S, Erkilinc G . Imp3 expression in benign and malignant thyroid tumors and hyperplastic nodules. Balkan Med J. 2015; 32(1):30-7. PMC: 4342135. DOI: 10.5152/balkanmedj.2015.15547. View

19.

Motylewska E, Borkowska M, Lawnicka H, Kuzdak K, Siejka A, Swietoslawski J . Dysregulation in IGF-1R, FGFR4 and βKlotho signaling in patients with medullary thyroid cancer. Neuro Endocrinol Lett. 2019; 40(1):29-35. View

20.

Gydee H, ONeill J, Patel A, Bauer A, Tuttle R, Francis G . Differentiated thyroid carcinomas from children and adolescents express IGF-I and the IGF-I receptor (IGF-I-R). Cancers with the most intense IGF-I-R expression may be more aggressive. Pediatr Res. 2004; 55(4):709-15. DOI: 10.1203/01.PDR.0000111282.98401.93. View